Combination of fixed low‐dose nivolumab and bendamustine in children with high‐risk relapsed/refractory classical Hodgkin lymphoma
A retrospective study of 18 pediatric patients with high-risk relapsed/refractory classical Hodgkin lymphoma demonstrated that a fixed low-dose combination of nivolumab and bendamustine achieved an 88% complete response rate, with 1-year progression-free survival (PFS) of 88.2% and overall survival (OS) of 94.4%.
Authors
- Aditya Narayan (ORCID: https://orcid.org/0000-0002-2427-6445)
- Akanksha Chichra
- Poonam Khemani
- Gaurav Narula (ORCID: https://orcid.org/0000-0002-8539-295X)
- Raghwesh Ranjan
- Chetan Dhamne (ORCID: https://orcid.org/0000-0002-3637-2880)
- Nirmalya Roy Moulik (ORCID: https://orcid.org/0000-0001-5650-3115)
- Shripad Banavali (ORCID: https://orcid.org/0000-0002-2039-6802)
- Tanuja M. Shet (ORCID: https://orcid.org/0000-0001-9294-9704)
- Venkata Rama Mohan Gollamudi
- Shyam Srinivasan (ORCID: https://orcid.org/0000-0003-2587-9181)
- Nidhi Dhariwal (ORCID: https://orcid.org/0000-0003-0146-2234)
- Sneha Shah (ORCID: https://orcid.org/0000-0002-9654-6694)
Institutions
- Homi Bhabha National Institute (IN)
- Bhabha Hospital (IN)
- Tata Memorial Hospital (IN)
- Advanced Centre for Treatment, Research and Education in Cancer (IN)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.1111/bjh.20148
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94